ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

ASCO 2016 Breast Cancer

ASCO 2016 Breast Cancer

OPT-822/821 vaccination did not show any improvement in progression-free survival as maintenance therapy compared with placebo for metastatic breast cancer. But in those patients who had an immune response, the vaccine did appear to show activity.

Among breast cancer survivors, black women are far less likely to receive BRCA testing and preventive surgery than white or Hispanic women.

Heavily pretreated women with metastatic breast cancer had significant improvements in progression-free survival and overall response rate when treated with the combination of utidelone plus capecitabine compared with capecitabine alone.

Postmenopausal women with early breast cancer benefit from extending AI therapy with letrozole from 5 to 10 years, and show no worsening of quality of life.

Directly engaging and recruiting patients online using social media will allow broader participation in cancer genomics research and hasten clinical advances.

The investigational biosimilar MYL-1401O has comparable efficacy and safety to the FDA-approved trastuzumab in metastatic HER2-positive breast cancer.

Subscribe to ASCO 2016 Breast Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.